Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma

Cancer Research

Volumn 71, Issue 14, 2011, Pages 4898-4907

  Purdue, Mark P ^a   Lan, Qing ^a   Bagni, Rachel ^b   Hocking, William G ^c   Baris, Dalsu ^a   Reding, Douglas J ^c   Rothman, Nathaniel ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD27 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 79960394814     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0165     Document Type: Article

References (49)

1. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990;323:1767-9.
2. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514-6. (Pubitemid 23362168)
3. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet 1991;337:805-9.
4. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003;32:527-33. (Pubitemid 36423125)
5. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004;23:6524-34. (Pubitemid 39265515)
6. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;7:27-38. (Pubitemid 43025390)
7. Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006;107:4101-8. (Pubitemid 43726819)
8. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 2007;28:704-12. (Pubitemid 46523368)
9. Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica 2007;92:960-9. (Pubitemid 350144243)
10. Skibola CF, Bracci PM, Nieters A, Brooks-Wilson A, De SS, Hughes AM, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol 2010;171:267-76.
11. Breen EC, van der Meijden M, Cumberland W, Kishimoto T, Detels R, Martinez-Maza O. The development of AIDS-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6. Clin Immunol 1999;92:293-9. (Pubitemid 29439676)
12. Breen EC, Boscardin WJ, Detels R, Jacobson LP, Smith MW, O'Brien SJ, et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clin Immunol 2003;109:119-29. (Pubitemid 37338618)
13. Widney D, Gundapp G, Said JW, van der Meijden M, Bonavida B, Demidem A, et al. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999;93:114-23. (Pubitemid 29523387)
14. Gu Y, Shore RE, Arslan AA, Koenig KL, Liu M, Ibrahim S, et al. Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study. Cancer Causes Control 2010;21:1323-33.
15. Saberi HF, Krop EJ, Scoccianti C, Krogh V, Palli D, Panico S, et al. Plasma cytokines and future risk of non-Hodgkin lymphoma (NHL): a case-control study nested in the Italian European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2010;19:1577-84.
16. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006;15:381-4. (Pubitemid 43348407)
17. Hsu SM, Hsu PL. Autocrine and paracrine functions of cytokines in malignant lymphomas. Biomed Pharmacother 1994;48:433-44.
18. Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol 2010;125:S272-83.
19. Purdue MP, Lan Q, Martinez-Maza O, Oken MM, Hocking W, Huang WY, et al. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood 2009;114:2730-2.
20. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 2000;21:251S-72S.
21. Hayes RB, Reding D, Kopp W, Subar AF, Bhat N, Rothman N, et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21:349S-55S.
22. Lubin JH, Colt JS, Camann D, Davis S, Cerhan JR, Severson RK, et al. Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect 2004;112:1691-6. (Pubitemid 40017291)
23. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A 1990;87:3127-31.
24. Lantz M, Malik S, Slevin ML, Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990;2:402-6.
25. Bargetzi MJ, Lantz M, Smith CG, Torti FM, Olsson I, Eisenberg SP, et al. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. Cancer Res 1993;53:4010-3. (Pubitemid 23267703)
26. Landmann R, Keilholz U, Scheibenbogen C, Brockhaus M, Gallati H, Denz H, et al. Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha. Cancer Immunol Immunother 1994;38:113-8. (Pubitemid 24063358)
27. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994;83:113-8. (Pubitemid 24016522)
28. Brockhaus M. Soluble TNF receptor: what is the significance? Intensive Care Med 1997;23:808-9.
29. Aderka D, Engelmann H, Shemer-Avni Y, Hornik V, Galil A, Sarov B, et al. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res 1992;11:157-9.
30. Trentin L, Pizzolo G, Zambello R, Agostini C, Morosato L, Sancetta R, et al. Leukemic cells in hairy cell leukemia and B cell chronic lymphocytic leukemia release soluble TNF receptors. Leukemia 1995;9:1051-5.
31. Hjelmstrom P. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. J Leukoc Biol 2001;69:331-9. (Pubitemid 32221435)
32. Spinas GA, Keller U, Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992;90:533-6.
33. Aukrust P, Froland SS, Liabakk NB, Muller F, Nordoy I, Haug C, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84:2136-43. (Pubitemid 24296369)
34. Bemelmans MH, Gouma DJ, Buurman WA. LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma. J Immunol 1993;151:5554-62. (Pubitemid 23332365)
35. Lens SM, Tesselaar K, van Oers MH, van Lier RA. Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 1998;10:491-9. (Pubitemid 28564378)
36. Goodwin RG, Alderson MR, Smith CA, Armitage RJ, VandenBos T, Jerzy R, et al. Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 1993;73:447-56. (Pubitemid 23143345)
37. Hintzen RQ, Lens SM, Lammers K, Kuiper H, Beckmann MP, van Lier RA. Engagement of CD27 with its ligand CD70 provides a second signal for T cell activation. J Immunol 1995;154:2612-23.
38. Kobata T, Agematsu K, Kameoka J, Schlossman SF, Morimoto C. CD27 is a signal-transducing molecule involved in CD45RA+ naive T cell costimulation. J Immunol 1994;153:5422-32. (Pubitemid 24377678)
39. Maurer D, Fischer GF, Fae I, Majdic O, Stuhlmeier K, Von JN, et al. IgM and IgG but not cytokine secretion is restricted to the CD27+ B lymphocyte subset. J Immunol 1992;148:3700-5.
40. Agematsu K, Kobata T, Yang FC, Nakazawa T, Fukushima K, Kitahara M, et al. CD27/CD70 interaction directly drives B cell IgG and IgM synthesis. Eur J Immunol 1995;25:2825-9.
41. van Oers MH, Pals ST, Evers LM, van der Schoot CE, Koopman G, Bonfrer JM, et al. Expression and release of CD27 in human B-cell malignancies. Blood 1993;82:3430-6. (Pubitemid 23356716)
42. Korner H, Cretney E, Wilhelm P, Kelly JM, Rollinghoff M, Sedgwick JD, et al. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. J Exp Med 2000;191:89-96. (Pubitemid 30043650)
43. Batten M, Fletcher C, Ng LG, Groom J, Wheway J, Laabi Y, et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004;172:812-22. (Pubitemid 38113737)
44. Czarneski J, Lin YC, Chong S, McCarthy B, Fernandes H, Parker G, et al. Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma. Leukemia 2004;18:597-606. (Pubitemid 38425876)
45. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996;56:5499-505. (Pubitemid 27011386)
46. House RV. Cytokine measurement techniques for assessing hypersensitivity. Toxicology 2001;158:51-8. (Pubitemid 32119496)
47. Thavasu PW, Longhurst S, Joel SP, Slevin ML, Balkwill FR. Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. J Immunol Methods 1992;153:115-24.
48. Gu Y, Zeleniuch-Jacquotte A, Linkov F, Koenig KL, Liu M, Velikokhatnaya L, et al. Reproducibility of serum cytokines and growth factors. Cytokine 2009;45:44-9.
49. Wong HL, Pfeiffer RM, Fears TR, Vermeulen R, Ji S, Rabkin CS. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomarkers Prev 2008;17:3450-6.